Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
News|Articles|September 17, 2026
Dr. Dina Khalaf Breaks Down 3 Trials Advancing AML, MDS Care
Author(s)Spencer Feldman
Fact checked by: CURE staff
Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.
Advertisement
Advertisement
In this Q&A, Dr. Dina Khalaf, a clinical associate professor in the University of Florida Division of Hematology and Oncology, discusses three clinical trials advancing treatment for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 AML/AMLSG 37-25.
Related to this article
Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.
Most cancers now have at least three or four treatment approaches, and an oncologist explained how cancer heterogeneity shapes the way patients respond.
Medicare will narrow ostomy suppliers to about eight national contracts, and advocate Ellyn Mantell says a poor fit can put patients in the hospital.
Dr. Andrew Ip answers common lymphoma questions, from diagnosis and treatment options to CAR T-cell therapy, side effects and hope for patients.
Dr. Doured Daghistani discusses how childhood cancer treatment, survivorship care and immunotherapy have evolved this Childhood Cancer Awareness Month.
After cancer, taking time to rest and travel can create space to heal, reconnect and remember that life is about more than simply surviving.
Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.
Advertisement
Advertisement